Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics (Oncosmart)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Italy
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-12-01
End date: 2017-03-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The advent of personalized cancer care demands for distributed diagnostic solutions to support clinical decisions and selection of the best therapeutic regimen. Supportive information can be obtained by analyzing the response of patient’s tissue to various treatment options. A specific opportunity arises in the field of cellular analysis, where the ex-vivo assessment of drug efficacy performed through drug response assays represents a powerful tool and, at the same time, a challenge due to the difficulty of maintaining in-vitro conditions that closely resemble in-vivo cell response. CellPly developed a novel in-vitro diagnostic (IVD) product to define cell response to anti-cancer drug treatment through integrated drug response analyses. Oncosmart platform includes a smart consumable, integrating a hybrid polymer/flexible-PCB micro-technology, an analytical instrument and diagnostic software. After patient’s tissue sampling, an automated process will carry out sample preparation, precise drug delivery and monitoring of cell response through time-lapse imaging. Cancer patients will benefit from more personalized cancer therapies, while the public health systems will reduce overall analysis and hospitalization costs and better allocate resources dedicated to cancer therapies. The Phase 1 project will set up the a quality-certified manufacturing chain and plan the validation of the platform in clinical setting in the field of acute leukemia; regulatory pathways to comply with CE-IVD and to seek reimbursement will be assessed; the commercialization strategy and associated business model(s) will be elaborated.

Keywords: microfluidics,lab on a chip,diagnostics,point of care,personalized medicine,predictive,oncology,medical device,healthcare,cancer,leukemia,in vitro,chemotherapy,drug testing,bedside
Development of an innovative and cost-efficient friction and wear reduction solution (TriboGlide) (TriboGlide)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: Sweden
Call: Small business innovation research for Transport and Smart Cities Mobility (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-09-01
End date: 2016-11-30
Duration (months): 3.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Friction and wear are encountered in all areas with relative motion between contacting surfaces. The resulting energy losses are huge: In economic terms friction and wear of materials are estimated to amount 5–8 % of an industrialized country’s GDP . Conventional solutions to reduce friction and wear include polishing, Diamond Like Carbons coatings (DLC), phosphating, bronze (bushings and pins) and plasma spraying. Applied Nano Surfaces’ (ANS) unique patented offering Triboconditioning® has been proved in over 70 customer projects to be a very high performant (achieving a reduction of friction up to 70% and wear up to 90%) and cost efficient solution in many industrial applications such as engines, compressors, stirling engines, pumps, hydraulic systems and various bushings and bearings. The cost of our technology is substantially lower than what our competitors can offer (up to 8100%) and it requires significantly lower investments in production. We are working with most of the major brands and companies (major auto brands/OEM and manufacturers like e.g. Mahle, GnuttiCarlo, Caterpillar, Daimler) that are continuously making efforts to increase fuel efficiency and increase performance of their products. The already signed license agreements are proof that we have an attractive solution to offer our customers. ANS has a core competence and expertise in the field of tribology, low friction coatings and international business development. The business model is based on a four-step customer approach that lets customers test the product in their own premises and then adjust it to the specific customer needs finalizing in license deals. The market potential for ANS’ technology is substantial and increasing. All mechanical systems in the world waste useful kinetic energy due to friction. With TriboGlide we aim to obtain an annual revenue of over 12 million € and quadruple our team by 2022.

Keywords: tribology,friction,wear,coating,automotive sector,fuel efficiency
Inner models and infinite computations (IMIC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Mathematics
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-07-01
End date: 2021-01-14
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

This proposal is in mathematical logic. It aims to study interactions between set theory and computability. More specifically, we want to apply techniques from inner model theory to computability and randomness. The development of modern set theory began with Paul Cohen's solution of Hilbert's first problem in 1964. Since then, set theory has been used to solve important problems in various areas of mathematics. Descriptive set theory studies definable sets of reals, for instance Borel and analytic sets, and computability studies computable functions and its higher analogues. We propose to develop applications of inner model theory in computability. Inner model theory is a major field of set theory which was pursued for instance by Ronald Jensen (recipient of the AMS Steel prize 2003 and Hausdorff medal 2015) and Hugh Woodin (recipient of the Hausdorff medal 2013). A major aim of this field is to determine the logical strength of theories. Recently, several new approaches for constructions of inner models have been studied, for example via strong logics by Menachem Magidor and Jouko Väänänen. We propose to follow this line of research and to study models constructed via ideas from infinite computation related to work of Joel David Hamkins and Philip Welch. We further propose to apply inner model theory and descriptive set theory to study random sequences. Algorithmic randomness is a central field in computability with connections to theoretical computer science, that has been studied intensively, for instance by Ted Slaman and Andre Nies. We aim to solve problems in the higher generalizations of algorithmic randomness.

Keywords: set theory,inner model theory,hypercomputation,descriptive set theory
Historical Grounding of Migration Decisions of the People at Environmental Risks (HoMe)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Germany,United States
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-05-01
End date: 2023-04-30
Duration (months): 36.0
Total project cost (EUR): 264669.12
EU funding (EUR): 264669.12
Participants: 2
Project status: CLOSED

The HoMe (Historical Grounding of Migration Decisions of People at Environmental Risks) project will provide insights on historical reasons of migration decisions (to migrate or to not migrate) of people at environmental risks. Current research on environmental migration claims that mostly the poor are migrating due to disaster. However, motivations of environmental non-migration go beyond resources constraints and are understudied and not yet understood as migration decisions. The factors contributing to non-migration are supposed to be not simply the inverse of those that motivate to migrate. Rather it is assumed, non-migration is also influenced by the settlement history of a community. Going beyond the state-of-the-art, this project will develop for the first time an analytical framework using Ostrom’s socio-ecological system framework for examining the historical grounding of migration decisions. Second, it will model how changes of the social, political and environmental conditions over time influence migration decisions using agent-based modelling. Third, the model will be used to explore possible future migration decisions based on alternative scenarios of changing societal and environmental conditions in the future making use of the findings from the influence of the historical grounding. This novel and timely study will significantly advance scientific knowledge on environmental migration and the respective modelling capabilities, particularly in the emerging field of 'Environmental Non-Migration'. Results will provide a major contribution to global adaptation policy frameworks, including the SDGs and the EU’s Agenda on Migration. The realisation of this cutting-edge project will substantially support the applicant to achieve higher level of professional maturity. It will be hosted by two excellent, highly experienced and internationally renowned institutes: University of Colorado Boulder (outbound) and Technische Universität Dresden (inbound).

Keywords: environmental non migration,historical grounding,migration decisions,environmental risk
Mimicking liver disease and regeneration in vitro for drug development and liver transplantation (HEPASPHER)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Sweden
Call: ERC Advanced Grant (ERC-2016-ADG, 2016)
Start date: 2017-09-01
End date: 2023-06-30
Duration (months): 70.0
Total project cost (EUR): 2413449.0
EU funding (EUR): 2413449.0
Participants: 1
Project status: SIGNED

The liver is a vital organ for synthesis and detoxification. The most significant liver diseases are hepatitis, non alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver steatohepatitis (NASH), carcinoma and cirrhosis. An additional and important cause of liver injury is adverse drug reactions (ADRs). In particular NAFLD is the most common liver disease affecting between 20% and 44% of European adults and 43-70% of patients with type 2 diabetes, and is one prime cause for chronic and end-stage liver disease, such as cirrhosis and primary hepatocellular carcinoma. This proposal is based on recent findings in the laboratory: The development of novel 3D spheroid system with chemically defined media allowing studies of chronic drug toxicity, relevant liver disease and liver function for 5 weeks in vitro, the finding of the role of miRNA in hepatocyte dedifferentiation and that hepatocytes during spheroid formation first de-differentiate but later in spheroids re-differentiate to an in vivo relevant phenotype. This forms the basis for the main objectives: i) to study diseased liver in vitro with identification of mechanisms, biomarkers and novel drug candidates for treatment of NAFLD and fibrosis, ii) evaluate drug toxicity sensitivity and mechanisms in diseased liver systems and iii) further develop methods for hepatocyte proliferation and regeneration in vitro for transplantation purposes, including genetic editing in cases of hepatocytes obtained from patients with genetically inherited liver diseases. This work is carried out in close contact with the Hepatology unit at the Karolinska Hospital partly using resources at the Science for Life Laboratory at Karolinska. It is anticipated that the project can provide with novel mechanisms, biomarkers and new targets for treatment of liver disease as well as novel methods for clinically applicable liver regeneration without the use of stem cells or transformed cells.

Keywords: liver regeneration,drug toxicity,in vitro models,drug development,nafld,liver disease
OsteomiR-Test – An In-Vitro Test for the Diagnosis of Osteoporosis and associated Fracture Risk (OsteomiR)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Austria
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2015, 2015)
Start date: 2015-07-01
End date: 2015-12-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

TAmiRNA aims to commercialize an in-vitro diagnostic test that is intended to predict fracture-risk in case of osteoporosis. The OsteomiR-Test meets an urgent clinical need by combining superior diagnostic performance with a simple test principle, thus, ensuring cost competiveness, good scalability and commercial success. Osteoporosis is a chronic skeletal disease characterized by systemic loss of bone strength and consequently high incidence of bone fractures. Osteoporotic fractures constitute one of the most common and costly health problems in the European Union (EU): costs related directly to fractures were EUR 24.3 billion in 2004 and will rise to EUR 76.8 billion by 2050 due to increasing life expectancy. Effective fracture prevention can be achieved through exercise, diet and drug treatment, but depends on reliable early prognosis of fracture risk. Currently, bone mineral density and clinical factors are the basis for prognosis of fracture risk. However, the low specificity of these tests limits efficient fracture prevention and creates an urgent clinical need for novel and better tests. The OsteomiR-Test measures a proprietary combination of circulating microRNAs from standard blood samples. The analyzed microRNAs provide a direct readout of bone metabolism, stress and biological age, and have been demonstrated to have a strong association with fracture-risk. It is a robust, easy-to-use test with good scalability. In order to commercialize the OsteomiR-Test, a detailed assessment of a market entry strategy is required. Therefore, TAmiRNA will i) develop health economic models to prioritize EU-countries for market launch, (ii) identify suitable manufacturing and distribution partners, (iii) define a strategy for IVD regulatory approval and, (iv) conduct a freedom-to-operate analysis. The results of this feasibility study will help to select target markets and define the cost structure of the test, and are therefore essential to successful commercialization.

Keywords: osteoporosis,risk prognosis,prognostic biomarker,circulating microrna
Radically Simplifying Electronics Engineering (Contunity)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-12-01
End date: 2020-03-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The demand of embedded systems, present in many everyday devices, is significantly growing due to the rise of automation, the Internet of Things and Industry 4.0 among others. As of now, most of the development is still performed through time-consuming, error-prone and costly manual engineering work, requiring highly skilled professionals and considerable know-how. Due to the increasing shortage of skilled labor and complexity of the devices, the development of electronics and embedded systems is currently facing a growing challenge, as the industry cannot keep the pace with ever shorter production cycles. Efficient alternative solutions automating the development process could significantly reduce the development effort (up to 90% time and 80% costs) of medium-sized companies, helping them close the skills gap and driving their digitalization. Contunity is a disruptive software solution that revolutionize the development of embedded systems through automation and simplification, empowering development teams to easily build embedded control units, without deep knowledge about electronics. We apply artificial intelligence and machine learning to every step of the development process to automatically generate the individual embedded code, hardware schematics and PCB-layout required for the manufacturing of the system. Our technology goes beyond current automation solutions by integrating hard- and software development in an easy-to-use software that eliminates current know-how barriers. We aim to reach a fully automated development process that delivers a superior quality to current manual engineering work. With Contunity we will help businesses to digitize their products and services, making electronics accessible for everyone. We estimate that 5 years after project completion, Contunity will allow us to hire 100 new employees until then and to generate €82,88M accumulated profit in 2022-2025, reaching a ROI of 17,84.

Keywords: embedded systems,desing software tool,digitalization,automation,industry 4 0,computational engineering,hardware schematics,pcb layout
Do Cardiac Health: Advanced New Generation Ecosystem (Do CHANGE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: Research and Innovation actions
Countries involved: Spain,Taiwan, Province of China,Belgium,Netherlands,Netherlands,United Kingdom,United Kingdom
Call: Self management of health and disease: citizen engagement and mHealth (H2020-PHC-2014-single-stage, 2014)
Start date: 2015-02-01
End date: 2018-07-31
Duration (months): 42.0
Total project cost (EUR): 5881000.0
EU funding (EUR): 4711000.0
Participants: 13
Project status: CLOSED

The primary objective of Do CHANGE is to develop a health ecosystem for integrated disease management of citizens with high blood pressure and patients with ischemic heart disease or heart failure. The system will give them access to a set of personalized health services in a near real-time fashion. This disruptive system will incorporate behavior change methods, such as “Do Something Different”, in conjunction with new innovative wearable/portable tools that can scan nature and volume of food and fluid intake, monitor behavior and clinical parameters in normal living situations. The objectives will be achieved by empowering patients with (1) tools and services, made available on smartphone or tablet and (2) the full control over the personal data they share with carers. To that extend a cyclic co-design methodology with end-users and health care professionals will be followed during the entire project. At the same time innovative end-user tools, including (1) a smart spatula for salt measurement, (2) a new artifact for fluid measurement and (3) a wearable food scan micro-spectrometer device, will be tested, (re-)designed and evaluated with patients and health professionals in Spain, NL and Taiwan. In view of the better balanced patient-care relationship, the traditional e-health telemonitoring will be enhanced with end-to-end trust assured transactions, secure storage, and ethical analytics of personal health data, making the patient an genuine stakeholder in his own cure processes and the ethical integration point of his own data. The proposal will be highly relevant to PCH 26 (ii): citizens’ life-style, socio-cultural values are continuously taken into account and a new range of mHealth tools is developed including a disruptive one from Taiwan. By providing concrete behavioral alternatives the new system will help patients to adhere to medical recommendations. Patient engagement and sanitized data logistics are to lead to significant health cost reductions.

Keywords: self management,empowering,data analytics,health cost reduction
Leveraging Networked Data for the Digital electricity Grid (Net2DG)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: A single, smart European electricity grid
Action type: Research and Innovation actions
Countries involved: Austria,Austria,Germany,Germany,Italy,Denmark,Denmark
Call: Next generation innovative technologies enabling smart grids, storage and energy system integration with increasing share of renewables: distribution network (H2020-LCE-2017-SGS, 2017)
Start date: 2018-01-01
End date: 2021-06-30
Duration (months): 42.0
Total project cost (EUR): 3591872.0
EU funding (EUR): 3591872.0
Participants: 10
Project status: CLOSED

Reliable and efficient electricity supply to geographically distributed customers is the main task of the Distribution System Operators (DSOs). An increasing number of grid-related data sources is in principle accessible to DSOs, but this information is in most cases not yet utilized for grid operation. Leveraging measurements and ICT reachability of Smart Meters and grid connected systems (such as Intelligent Electronic Devices) for digital distribution grid operation is challenging as it requires resilient and secure data collection, and data-quality aware processing and distribution system control solutions. The Net2DG project will develop a proof-of-concept solution based on off-the-shelf computing hardware that uses existing communication technologies to leverage measurement capabilities of Smart Meters and DER inverters deployed in low-voltage (LV) grids. The solution will correlate this data with information from existing DSO subsystems in order to provide novel LV grid observability applications for voltage quality, grid operation efficiency and LV grid outage diagnosis. The resulting observability is subsequently used by specifically developed robust control and coordination approaches, which utilize existing actuation capabilities for voltage quality enhancement and loss minimization in the LV grid. The use of off-the shelf components, the system level resilience and security solution, and the offered customizability of the Net2DG approach specifically address the needs of small and medium-sized DSOs (less than 100.000 clients). Therefore, the Net2DG solution will make small and medium-sized DSOs early adopters of digital technologies for LV outage diagnosis, grid operation efficiency and voltage quality. The Net2DG solutions will be developed by a consortium including two small and medium-sized DSOs from two different European countries, academic partners, SME and startup technology companies, as well as Smart Meter and inverter vendors.

Keywords: low voltage grid observability and control,smart meters,der inverters,voltage quality,grid operation efficiency,outage diagnosis,small and medium sized distribution system operators